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Aims Modern imaging technology allows us the visualization of coronary artery calciﬁcation (CAC), a marker of subclinical
coronary atherosclerosis. The prevalence, quantity, and risk factors for CAC were compared between two studies
with similar imaging protocols but different source populations: the Multi-Ethnic Study of Atherosclerosis (MESA) and
the Heinz Nixdorf Recall Study (HNR).
Methods
and results
The measured CAC in 2220 MESA participants were compared with those in 3126 HNR participants with the
inclusion criteria such as age 45–75 years, Caucasian race, and free of baseline cardiovascular disease. Despite
similar mean levels of CAC of 244.6 among participants in MESA and of 240.3 in HNR (P ¼ 0.91), the prevalence
of CAC . 0 was lower in MESA (52.6%) compared with HNR (67.0%) with a prevalence rate ratio of CAC . 0
of 0.78 [95% conﬁdence interval (CI): 0.72–0.85] after adjustment for known risk factors. Consequently, among par-
ticipants with CAC . 0, the participants in MESA tended to have higher levels of CAC than those in HNR (ratio of
CAC levels: 1.39; 95% CI: 1.19–1.63), since many HNR participants have small (near zero) CAC values.
Conclusions The CAC prevalence was lower in the United States (MESA) cohort than in the German (HNR) cohort, which may
be explained by more favourable risk factor levels among the MESA participants. The predictors for increased levels
of CAC were, however, similar in both cohorts with the exception that male gender, blood pressure, and body mass
index were more strongly associated in the HNR cohort.
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First serious cardiac events are often fatal, and half of all coronary
heart disease (CHD) deaths are sudden coronary deaths and occur
out of the hospital.
1–3 A continued emphasis on primary and sec-
ondary prevention programmes may be a key step in reducing
mortality due to CHD.
1–4
Individual risk prediction algorithms are currently based on
cohorts of different countries.
4–9 In low-risk subjects (,10%
risk of a hard cardiac event within 10 years), life style changes
are recommended with a repeat check-up after 3–5 years.
However, it is recommended that high-risk subjects (.20% risk
of hard events, myocardial infarction, or CHD death within 10
years) should undergo risk factor reduction including drug treat-
ment. In intermediate risk subjects, further tests are suggested
for risk stratiﬁcation.
7–9 Calcium screening for the detection of
coronary artery calciﬁcation (CAC) belongs to the currently avail-
able tests.
10–12
Two prospective studies have simultaneously been initiated, the
MESA (Multi-Ethnic Study of Atherosclerosis)
13 and the Heinz
Nixdorf Recall Study (HNR) (risk factors, evaluation of coronary
calcium and lifestyle study), both of which study the value of
CAC levels for risk prediction.
14 Their cross-sectional data on
the baseline characteristics have previously been published.
15–24
The aim of this study is to compare the prevalence of cardiovas-
cular risk factors and their association with CAC between the
United States and Germany.
Methods
Study populations
The MESA study recruited 6814 participants between the years 2000
and 2002 across six centres in the United States with participants
recruited using locally available resources, including lists of residents,
dwellings,telephoneexchanges,divisionofmotorvehiclelists,consumer
lists, voter registration lists, and census data. Each site recruited an
approximately equal number of men and women, according to pre-
speciﬁed age and race/ethnicity proportions. Participants were
between 45 and 84 years of age and identiﬁed themselves as one of
Caucasian, African-American, Hispanic, or Chinese.
13 For this com-
parison of the two study cohorts, only Caucasians aged 45–75
years with complete information on risk factors, blood pressure and
lipid-lowering medication and CAC, and without clinically overt cardi-
ovascular disease were included (Figure 1 and 2).
The HNR recruited a total of 4814 Caucasians between 45 and 75
years of age from three neighbouring cities in Germany between the
years 2000 and 2003 in a single centre with a response rate of
55.8%.
18 Participants were a random sample derived from mandatory
citizen registries and provided to the study centre. The study was cer-
tiﬁed according to DIN EN ISO 9001:2000, and re-certiﬁed in 2006.
For both studies, approval was provided by the local institutional
review boards.
Clinical data
ThetraditionalcardiovascularriskfactorsthatarepartoftheFramingham
risk scoring algorithm
9 were measured in both studies. In addition,
Figure 1 Multi-Ethnic Study of Atherosclerosis (MESA) decision tree for inclusion in joint study.
Comparison of CAC prevalence between MESA and HNR 2783body mass index (BMI; kg/m
2) was computed on the basis of direct
measurements of height and weight. All medication utilization
reported was based on participants’ self-report.
Standard enzymatic methods were used to measure total cholesterol,
high-densitylipoprotein(HDL)-cholesterol(HDL-C),andtriglycerides.
13,14
Low-density lipoprotein (LDL)-cholesterol (LDL-C) was calculated
with the Friedewald equation in MESA
17,22 and measured directly in
HNR.
19,20 Blood samples were obtained after a 12 h fasting in
MESA. In HNR, participants were fasting 9.7+4.9 h (median 12 h)
before blood sampling, with 34.4% having fasted for ,6h .
In both studies, blood pressure was measured using an oscillo-
graphic method with two different systems (Dynamap
w, J&J, USA
and HEM-705CP, Omron, Hoofddrop, NL).
13,14,18 The mean values
of the second and third of three measurements taken at least 2 min
apart were used. Hypertension was deﬁned in both studies as blood
pressure .140/90 mmHg or use of antihypertensive medication.
18,22
In both studies, participants were considered diabetic if they
were taking anti-diabetic medication or had a fasting glucose of
.126 mg/dL.
19,22 And smoking history was categorized to (i) currently
smoking, (ii) former, deﬁned as not smoking within the past 30 days in
MESA and as stopped smoking (a) within the past year or (b) more
than 1 year ago in the HNR, and (iii) never.
17,23
The use of lipid-lowering medication was documented. This
included HMG CoA reductase inhibitors (‘statins’), ﬁbrates, bile acid
sequestrants, and nicotinic acid derivatives.
17,20
Electron beam and multi-slice computed
tomography
Participants received the scanning examination ﬁrst and were then
entered into MESA, whereas, in HNR, participants were seen and
tested in the study centre before electron beam CT (EBCT) was per-
formed.
13,14 Non-enhanced EBCT scans were performed with a C-100
or C-150 scanner (GE Imatron, South San Francisco, USA) in three
MESA and the HNR centres. In addition, three other MESA centres
used a ﬁrst-generation multi-slice CT (MSCT).
13 The EBCT scanners
were operated in the single-slice mode with an image acquisition
time of 100 ms and a section thickness of 3 mm. Prospective ECG-
triggering was done at 80% of the R–R interval for EBCT. Each partici-
pant was scanned twice in MESA and once in HNR.
15,16,19
Figure 2 Heinz Nixdorf Recall Study (HNR) decision tree for inclusion in joint study.
R. Erbel et al. 2784In MESA, scans were read centrally at the Los Angeles Biomedical
Research Institute at Harbor–UCLA Medical Center.
24 In HNR, the
two radiology departments scanned and analysed the CAC score
blinded and independently.
14,19 In both studies, CAC was deﬁned as
a hyper-attenuating foci of at least four contiguous pixels with a CT
density of  130 Hounsﬁeld Units. The area of each focus was
measured and the CAC score was determined using the methods of
Agatston et al.
25 The CAC score is the product of the area of each
focus of detectable CAC and a factor rated one through four dictated
by the maximum CT density within that focus. The total (Agatston)
CAC score was computed by summing-up the CAC scores of all
foci in the epicardial coronary system without phantom adjustment.
Agreement with regard to the presence of CAC was high in MESA
(k ¼ 0.90–0.93)
24 and interclass correlation coefﬁcient for CAC
scoring of 0.99. In the HNR, inter-scan variability was 5–8%, and for
inter-institutional readings of the two EBCT centres a k-value of
0.94 in 250 scans was found.
26
Statistical analysis
The MESA and HNR cohorts included in this comparison consisted of
2220 and 3126 Caucasian participants, respectively, between 45 and 75
years of age. Figures 1 and 2 demonstrate both the number of and
reason for each exclusion of participants from either study from the
current comparison.
The Framingham risk score was calculated for men and women to
estimate the 10 year risk of a CHD event.
9
Data are given as mean (SD) or frequency (%). Simple unadjusted
differences in baseline data between MESA and HNR are statistically
evaluated using Student’s t-test for continuous or x
2 test for categori-
cal variables. We compared the prevalence of CAC . 0 between
MESA and HNR using relative risk regression with robust standard
errors. We used this approach to estimate the prevalence rate ratio
(RR) rather than logistic regression because the prevalence of
CAC . 0 is high, and hence the odds ratio is a poor estimate of the
RR.
27 In adjusted models, we controlled for age, sex, blood pressure,
BMI, triglycerides, total cholesterol, HDL-C, glucose, current
smoking, pack years, and medication use (blood pressure, diabetes,
and cholesterol lowering).
Among those with CAC . 0, we modelled the log-transformed
amount of CAC as a linear function of study (MESA vs. HNR) and
the covariates described above. The exponentiated coefﬁcients from
these models are presented, and these are interpreted as a multiplica-
tive increase in average CAC amount. The above analyses were
repeated stratifying by sex. In addition, for the pooled models, we
tested for interactions between each risk factor and study (MESA vs.
HNR) to determine whether the risk factor associations with either
presence or level of CAC differed between the study populations.
All analyses were performed with SAS, version 9.1.3. All statistical
tests were two sided and at the 5% level of statistical signiﬁcance.
Results
After all exclusion criteria were applied, the ﬁnal study population
consisted of 2220 subjects from MESA and 3126 from HNR. The
baseline demographics and the results of the CAC scoring for
men and women are shown in Table 1. The prevalence of most car-
diovascular risk factors was lower in MESA than in HNR. In MESA,
blood pressure values were lower and antihypertensive medications
are more often used than in HNR. Current smoking was much more
prevalent in HNR, although due to a higher rate of former smokers
in MESA, pack years of smoking were very similar between the two
cohorts. For total cholesterol a between-study difference of
35.7 mg/dL and for LDL-C a difference of 29.6 mg/dL were found,
with cholesterol values lower in MESA. Average HDL-C was also
lower in MESA (7.1 mg/dL estimated difference). Lipid-lowering
medication was much more common in MESA than in HNR (17.4
vs. 8.2%). The proportion of treated diabetic participants was
similar between the two populations. The 10 year Framingham
risk score was slightly lower in the MESA cohort than in the HNR
cohort (10+7v s .1 1+8%, P , 0.0001).
For male and female participants, the prevalence of zero CAC
was substantially higher in MESA than those in HNR, while the
prevalence of those with small amounts of CAC was much
higher in HNR (Figure 3). There was a slightly higher prevalence
of CAC . 400 Agatston score units in MESA compared with
those in HNR.
Table 2 provides the RR of CAC . 0 and 95% CI for MESA
relative to the HNR cohort. For MESA participants, the rate of
prevalent CAC was 22% less (95% CI, 15–28) when adjusted
for traditional risk factors. For male participants, the adjusted
prevalence of CAC . 0 was 38% lower in the MESA participants
than in the HNR participants (95% CI, 27–48) whereas for
female participants the adjusted prevalence of CAC . 0w a s
18% lower (95% CI, 11–25).
Table 3 displays the estimated ratio of the average amount of
CAC for participants in the MESA and HNR cohorts among
those with a measured CAC . 0 at baseline. Among participants
with CAC and adjusted for risk factors, MESA participants had an
estimated 39% (95% CI, 19–63) higher average level of CAC due
to the large number of low CAC values among HNR participants.
Table 4 provides the prevalence rate ratio (RR) of CAC being
present within the MESA and HNR cohorts. The association of
age with CAC presentation was nearly identical between the
two cohorts, with each 10 years of age increasing the prevalence
of CAC by approximately 47% (for the tested life span from 45
to 75 years). The RR associated with male gender (MESA: RR
1.61 vs. HNR: RR 2.20; P ¼ 0.0063) and BMI (MESA: RR 1.00 vs.
HNR: 1.05; P   0.0001) were signiﬁcantly lower in MESA than in
HNR. As a sensitivity analysis for low CAC values, we performed
the calculation using a cut-off value of 10 instead of zero in order
to account for possible different measurement protocols. The cal-
culation showed only minor shifts in parameters.
Table 5 demonstratestheestimated ratio ofthe average amountof
CAC (among those with CAC . 0) for the MESA and HNR cohorts
using log-linear regression analysis. In MESA, age was a stronger pre-
dictor for CAC (2.38 in MESA vs. 1.92 in HNR, P ¼ 0.013 for inter-
action). Blood pressures were not strongly associated with CAC in
MESA, whereas in HNR systolic and diastolic blood pressures
were strongly positively and negatively associated with CAC respect-
ively. The proportion of the variation explained by these models was
nearly identical for the MESA participants (r
2 ¼ 21.4%) compared
with the HNR participants (r
2 ¼ 21.2%).
Discussion
The main ﬁndings of our study were: (i) the prevalence of CAC . 0
was lower in the MESA population than in the HNR population. (ii)
Comparison of CAC prevalence between MESA and HNR 2785Differences in how speciﬁc risk factors affected either the preva-
lence of CAC . 0 or the level of CAC pertained to age, male
gender, BMI, and blood pressure. Risk factors in MESA were
lower than in HNR. The results for these two studies appear to
be representative of the underlying populations and so differences
may be due to differences in the distribution of modiﬁable risk
factors between the United States and Germany.
The prevalence of participants with CAC . 0 was lower in the
MESA than those in the HNR population, which was surprising.
Our study showed not only a lower prevalence but also lower
median CAC values in MESA compared with HNR for men and
women. The fact that a much higher proportion of HNR partici-
pants had low CAC scores (rather than zero scores) could be
explained if the HNR scanners were detecting more noise than
the MESA scanners. However, we determined that the presence
of a small amount of CAC in HNR was associated with the stan-
dard risk factors, indicating that these small values are unlikely to
be due primarily to noise artefacts.
On the other hand, participants with CAC . 400 were found
slightly more often in the MESA cohort than in the HNR cohort.
CAC represents the long-term effect of risk factor exposure,
and the observed risk factor values in MESA and HNR reﬂect
only the current level. Alternatively, there were selected risk
factors that had a worse proﬁle in MESA than in HNR, such as
BMI and HDL-C.
With respect to cardiovascular risk, chronological age rep-
resents a very strong risk factor in current algorithms.
5–9Measures
of CAC seem to be related to survival.
11,12,28 The mean age, but
not the range, was slightly different between MESA and HNR,
but this difference in ages was not sufﬁcient to explain the differ-
ence in prevalence of CAC that we observed.
16,28,29
Women have much lower values of CAC than men and start to
develop CAC later.
16,19 Therefore, risk assessment for increased
risk of cardiac outcomes should consider both age and sex.
30,31
Gender was one of the most important variables when tested
for RR of CAC being present. In addition, gender was one of the
two variables with a signiﬁcantly different association with CAC
between the two studies. Both in men and women, the prevalence
of CAC ¼ 0 is higher in MESA compared with HNR. This may in
part be attributable to differences in risk factor control in the
...................................................... ......................................................
...............................................................................................................................................................................
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Table 1 Baseline demographics of Multi-Ethnic Study of Atherosclerosis (MESA) and the Heinz Nixdorf Recall Study
(HNR) male and female participants
MESA (n 5 2220) HNR (n 5 3126)
Men (n 5 1080) Women (n 5 1140) Men (n 5 1466) Women (n 5 1660)
Age, years 60.6 (8.8) 59.9 (8.6) 58.7 (7.5) 58.9 (7.7)
Systolic blood pressure, mmHg 123.0 (17.8) 120.6 (21.2) 137.4 (19.3) 127.2 (20.8)
Diastolic blood pressure, mmHg 74.2 (9.0) 67.1 (9.6) 84.3 (10.5) 78.8 (10.4)
Antihypertensive medication 31.6 29.2 27.2 27.6
Current smoker,% 11.9 13.1 24.6 22.8
Former smoker, % 48.3 41.3 45.2 22.5
Pack years of smoking
a, years 21.0 (29.1) 9.5 (16.5) 18.7 (34.7) 12.2 (19.9)
Body mass index, kg/m
2 28.1 (4.2) 27.7 (6.0) 27.9 (3.8) 27.2 (4.8)
Total cholesterol, mg/dL 189 (33) 201 (33) 228 (37) 234 (39)
LDL-C, mg/dL 118 (29) 117 (31) 148 (35) 146 (37)
HDL-C, mg/dL 45 (12) 59 (16) 52 (14) 66 (17)
Triglycerides, mg/dL 129 (66) 127 (66) 161 (115) 129 (77)
Lipid-lowering medication,% 19.6 15.4 8.0 8.4
Glucose, mg/dL 101 (24) 94 (16) 113 (29) 106 (22)
Treated diabetes mellitus,% 4.4 3.2 5.7 3.3
Framingham risk score, % in 10 years 13 (8) 6 (4) 15 (9) 7 (5)
Framingham risk score median (Q1–3) 11 (7.4 and 17.3) 5 (3.3 and 7.7) 14 (9 and 18) 2.6 (3 and 9)
Proportion of subjects with CAC (Agatston) score units
0, % 32.4 61.8 18.1 46.2
1–10,% 6.9 5.8 13.2 21.6
11–100, % 23.0 17.2 29.3 18.9
101–400,% 19.9 10.3 23.9 9.5
401þ,% 17.9 5.0 15.4 3.7
Median CAC (Agatston) score units (Q1–3) 30.6 (0–246.9) 0 (0–24.7) 52.6 (0– 222.5) 1.3 (0–31.6)
Mean log (CAC þ 1) 3.17 (2.64) 1.52 (2.33) 3.58 (2.33) 1.77 (2.09)
Mean log (CAC þ 1) where CAC . 0 4.69 (1.76) 3.98 (1.79) 4.36 (1.79) 3.31 (1.77)
Values represent mean+SD or percentages.
aAmong smokers and past-smokers.
R. Erbel et al. 2786United States vs. Germany. This is supported by higher use of anti-
hypertensive and lipid-lowering medication in the United States
(see below), which is expected to be similarly effective in men
and women. Risk factor control using medication or life-style inter-
ventions may also have been initiated earlier in lives of United
States compared with German participants.
Blood pressure can be regarded as a strong risk predictor for both
cardiac and cardiovascular events.
5–9 Blood pressure was lower
among MESA participants than among HNR participants. This
difference in blood pressure levels may be part of the explanation of
the lower degree of CAC in the MESA compared with the HNR
cohorts. One factor that might explain some of this observed differ-
ence in blood pressure could be the different oscillographic systems
that were used, but not being able to explain the total difference.
21
More participants in MESA compared with those in HNR
received antihypertensive treatment (30 vs. 27%, P , 0.0172),
Figure 3 Comparison of the distribution of coronary artery calcium in Multi-Ethnic Study of Atherosclerosis (MESA) (top) with the
distribution of coronary artery calcium in Heinz Nixdorf Recall Study (HNR) (bottom) in terms of log(CAC þ 1). Data from the MESA and
the HNR.
................................................................................
................................................................................
................................................................................
Table 2 Prevalence rate ratio (RR) of coronary artery
calcium greater than zero: Multi-Ethnic Study of
Atherosclerosis (MESA) vs. Heinz Nixdorf Recall Study
(HNR)
n Crude RR (95% CI) Adjusted RR
a (95% CI)
Overall
HNR 3126 Reference Reference
MESA 2220 0.70 (0.65–0.74) 0.78 (0.72–0.85)
Women
HNR 1660 Reference Reference
MESA 1140 0.75 (0.70–0.80) 0.82 (0.75–0.89)
Men
HNR 1466 Reference Reference
MESA 1080 0.56 (0.49–0.64) 0.62 (0.52–0.73)
aAdjusted for age, male, blood pressure, body mass index, triglycerides, total
cholesterol, HDL-cholesterol, glucose, current smoker, pack years and medication
use (blood pressure, diabetes, and cholesterol lowering).
................................................................................
................................................................................
................................................................................
Table 3 Estimated ratio of the amount of coronary
artery calcium (CAC) and 95% CI among participants
with CAC greater than zero: Multi-Ethnic Study of
Atherosclerosis (MESA) vs. Heinz Nixdorf Recall Study
(HNR) cohorts
n Crude ratio
(95% CI)
Adjusted ratio
a
(95% CI)
Overall
HNR 2093 Reference Reference
MESA 1166 1.73 (1.51–1.98) 1.39 (1.19–1.63)
Women
HNR 893 Reference Reference
MESA 436 2.09 (1.65–2.58) 1.68 (1.28–2.20)
Men
HNR 1200 Reference Reference
MESA 730 1.40 (1.18–1.66) 1.24 (1.02–1.52)
aAdjusted for age, male, blood pressure, body mass index, triglycerides, total
cholesterol, HDL-cholesterol, glucose, current smoker, pack years, and
medication use (blood pressure, diabetes, and cholesterol lowering).
Comparison of CAC prevalence between MESA and HNR 2787and there was less untreated hypertension (10 vs. 24%, P ,
0.0001). Blood pressure control in Germany is far from the
optimal that has been reported for other countries.
32,33 The
poor control of blood pressure and thereby the wider range
may be an explanation for the signiﬁcant association of blood
pressure and CAC amount in HNR study but not in MESA. The
importance of blood pressure as a risk factor is, however, under-
lined by the fact that in both studies antihypertensive medication
was a highly signiﬁcant predictor of CAC.
Previous studies have shown that tobacco use is a major avoidable
cause of cardiovascular diseases.
34 Strong efforts have been made to
bansmokingintheUnitedStates,buteffortsinEuropebeganlaterand
have been less effective.
35 This may explain why the prevalence of
current smoking is lower in MESA than in HNR. MESA had much
higher rates of former smokers, and roughly equivalent average
pack years of smoking, supporting the success ofrecentanti-smoking
efforts in the United States. The interactions between study and the
smoking variables were not signiﬁcant, however, suggesting that the
association between smoking and CAC was similar in both studies.
Total cholesterol (TC) and LDL-C are regarded as traditional
risk factors.
5–9 In the MESA cohort, mean TC was ,200 mg/dL,
LDL-C ,130 mg/dL, and triglycerides ,150 mg/dL, which are
...............................................................................................................................................................................
Table 4 Prevalence rate ratio (RR) and 95% CI of coronary artery calcium greater then zero: Multi-Ethnic Study of
Atherosclerosis (MESA; n 5 2220) vs. Heinz Nixdorf Recall (HNR) Study (n 5 3126)
MESA (95% CI) P-value HNR (95% CI) P-value Interaction P-value
Age, 10 years 1.47 (1.38–1.55) ,0.0001 1.46 (1.35–1.57) ,0.0001 0.9397
Male 1.61 (1.46–1.79) ,0.0001 2.20 (1.93–2.50) ,0.0001 0.0063
Systolic blood pressure, 10 mmHg 1.02 (0.99–1.06) 0.1933 1.04 (0.99–1.08) 0.1129 0.7732
Diastolic blood pressure, 10 mmHg 1.03 (0.97–1.09) 0.3436 1.03 (0.95–1.10) 0.5917 0.9094
Antihypertensive medication 1.12 (1.01–1.25) 0.0358 1.18 (1.03–1.34) 0.0127 0.6594
Current smoker 1.26 (0.98–1.29) 0.1021 1.36 (1.16–1.58) ,0.0001 0.1717
Pack years, 10 years 1.05 (1.01–1.10) 0.0201 1.02 (0.97–1.06) 0.5557 0.1194
Body mass index, kg/m
2 1.00 (1.00–1.01) 0.2727 1.05 (1.04–1.07) ,0.0001 <0.0001
Triglycerides, 10 mg/dL 0.99 (0.98–1.00) 0.0077 1.00 (0.99–1.01) 0.9532 0.2519
Total cholesterol, 10 mg/dL 1.03 (1.01–1.04) 0.0001 1.12 (1.01–1.04) ,0.0001 0.9768
HDL-cholesterol, 5 mg/dL 0.97 (0.96–0.98) ,0.0001 0.99 (0.97–1.01) 0.2535 0.2113
Lipid-lowering medication 1.53 (1.31–1.78) ,0.0001 1.33 (1.05–1.67) 0.0172 0.4365
Glucose, 10 mg/dL 1.01 (0.98–1.04) 0.4631 1.01 (0.97–1.04) 0.7184 0.8680
Treated diabetes 1.85 (1.18–2.95) 0.0085 1.55 (1.03–2.33) 0.0342 0.6455
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 5 Estimated ratio of the amount of log(CAC) and 95% CI: Multi-Ethnic Study of Atherosclerosis (MESA; n 5 1166)
and the Heinz Nixdorf Recall Study (HNR; n 5 2093)
MESA (95% CI) P-value HNR (95% CI) P-value Interaction P-value
Age, 10 years 2.38 (2.08–2.72) ,0.0001 1.92 (1.71–2.17) ,0.0001 0.0262
Males 2.23 (1.76–2.85) ,0.0001 3.18 (2.67–3.78) ,0.0001 0.0203
Systolic blood pressure, 10 mmHg 1.04 (0.97–1.12) 0.2555 1.14 (1.07–1.21) ,0.0001 0.0609
Diastolic blood pressure, 10 mmHg 1.11 (0.96–1.28) 0.1437 0.85 (0.77–0.95) 0.0043 0.0054
Antihypertensive medication 1.32 (1.06–1.64) 0.0122 1.45 (1.22–1.72) ,0.0001 0.5281
Current smoker 1.12 (0.80–1.57) 0.5062 1.21 (1.00–1.48) 0.0527 0.9962
Pack years, 10 years 1.07 (1.02–1.11) 0.0022 1.08 (1.04–1.12) ,0.0001 0.3105
Body mass index 1.01 (0.99–1.03) 0.5252 1.00 (0.98–1.01) 0.6705 0.6887
Triglycerides, 10 mg/dL 1.00 (0.98–1.02) 0.9250 1.00 (0.99–1.01) 0.9503 0.5674
Total cholesterol, 10 mg/dL 1.02 (0.99–1.06) 0.2229 1.04 (1.01–1.06) 0.0012 0.5919
HDL-cholesterol, 5 mg/dL 1.00 (0.96–1.04) 0.8672 0.99 (0.96–1.02) 0.5535 0.4422
Lipid-lowering medication 1.20 (0.95–1.53) 0.1246 1.44 (1.09–1.90) 0.0104 0.3470
Glucose, 10 mg/dL 0.99 (0.95–1.03) 0.6057 1.02 (0.99–1.05) 0.2760 0.5574
Treated diabetes 1.70 (1.06–2.71) 0.0266 1.21 (0.81–1.79) 0.3482 0.2806
Model ﬁt statistics
R
2 21.4% 21.2% 22.6%
R. Erbel et al. 2788regarded as desirable, nearly optimal, and normal.
9 The results
seem to be in line with general trends in the United States.
36
LDL-C was selected as the primary target of cholesterol-lowering
therapy,
9 resulting in an increased use of lipid-lowering medi-
cation.
36 In HNR, signiﬁcantly higher concentrations were
observed which is representative for Germany.
37,38 The associ-
ation between TC and CAC was not signiﬁcantly different
between the two studies, though was qualitatively stronger in
HNR than in MESA. Similarly, HDL was only signiﬁcantly protective
(for the presence of CAC . 0) in MESA, though the interaction
was not statistically signiﬁcant. The prevalence of cholesterol
lipid-lowering medication was different between the two studies.
The effect of these medications on CAC should be further inves-
tigated prospectively in each of these study populations once longi-
tudinal data become available.
In both studies glucose levels were not related to risk of CAC
independent of diabetic status, but treated diabetes was signiﬁcantly
associatedwithCAC.However,inHNRnotallsubjectswerefasting
andglucosetolerancetestswerenotperformedinbothstudies.The
RR of prevalent CAC was 55% higher for treated diabetics com-
pared withothers inMESA,and 65%higher inHNR. Theinteraction
between study and diabetes was non-signiﬁcant.
Limitations of the study
It was not possible to compare the full cohorts of either study. To
allow for best possible comparability between the two cohorts,
identical inclusion criteria were employed to identify all partici-
pants without prevalent cardiovascular disease. Thereby, the selec-
tion bias could be minimized, which otherwise may have been
caused by differences in recruitment strategies.
The prevalence and levels of cardiovascular risk factors are very
different in the two cohorts of ostensibly healthy persons but both
seem to be representative for each of the two countries. This is a
cross-sectional study and so it is not possible to establish the direc-
tion of any association between risk factors and CAC.
39 In addition,
there is a possibility of unmeasured confounders such as lifestyle
and dietary history that could explain some of the observed differ-
ences between the cohorts. It is possible that differences between
the types of scanners used in both studies could explain a small
part of the observed population differences in CAC levels. It has
to be taken into account that the MESA performed a calculation
to estimate the LDL-C concentration whereas it was directly
measured in HNR. The assay used met the requirements for accu-
rate testing even from non-fasting individuals.
40 However, the
differences between MESA and HNR cannot be attributed to
these methodological differences because TC also showed the
same magnitude of difference in the same direction.
In the present analysis, a socio-economic comparison has not
been included, because socio-economic variables such as
income—due to differences in services, conversion in income
from Euros to Dollars, etc. and education—given the United
States cost structure of higher education, are difﬁcult to
compare between the two countries.
Conclusions
Coronary artery calciﬁcation prevalence was lower in the United
States (MESA) cohort than the German (HNR) cohort. This was
partially but not fully explained by generally more favourable risk
factor levels among the MESA participants. This could be shown
for men and women. CAC was signiﬁcantly associated with age,
gender, current smoking, treated diabetes, hypertension, and
hypercholesterolaemia. Risk factor associations were comparable
across the two studies, with the exception that male
gender, blood pressure, and BMI were more strongly associated
with CAC in the German cohort. It is possible that the difference
in CAC could be attributed to different efforts towards risk
factor elimination in the two countries. Germany shows higher
rates of hypercholesterolaemia and smoking, but less obesity
and use of lipid-lowering medication. In particular, the effect of
the higher rates of untreated hypertension in the German popu-
lation should be further investigated prospectively and could be
responsible for an earlier onset of subclinical coronary
atherosclerosis.
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Braid-like appearance of the coronary artery in Kawasaki disease: typical
computed tomography and angiography ﬁndings
Young Jin Kim, Hye-Jeong Lee, Jin Hur, Ji Eun Nam, Kyu Ok Choe, Yangsoo Jang, and Byoung Wook Choi*
Department of Radiology, Yonsei University College of Medicine, Severance Hospital, 250 Seongsanno, Seodaemun-gu, Seoul 120-752, Republic of Korea
*Corresponding author. Tel: þ82 2 2228 7400, Fax: þ82 2 393 3035, Email: bchoi@yuhs.ac
A 19-year-old man was admitted due to exertional chest pain. He
had been diagnosed with Kawasaki disease when he was 4
months old. He underwent coronary angiography, which showed
total occlusion of the proximal left anterior descending coronary
artery and 85% luminal narrowing of the proximal left circumﬂex
coronary artery. His right coronary artery (RCA) demonstrated a
typical ‘braid-like appearance’ on coronary angiography. The braid-
like appearance of the RCA was subsequently excellently visualized
in 3D volume rendering images, curved multiplanar reformation
images, and axial images of coronary computed tomography and
angiography.
In Kawasaki disease, panarteritis occurs in the acute phase and
coronary artery aneurysms develop in the subacute phase. In the
chronic phase, aneurysms undergo regression or remodelling. Intra-
mural collateral arteries may develop in occluded segments of the
coronary arteries, and they appear as ‘arteries within the artery’
and show a braid-like appearance.
Panel A–B. Coronary angiography (A) and 3D volume rendering
image of CT (B) show the braid-like appearance of the right
coronary artery.
Panel C–D. Curved multiplanar (C) and axial (D) CT images demonstrate new small collateral arteries braided together within the
conﬁnes of the original artery. This phenomenon of arteries within an artery is pathologically unique to Kawasaki disease.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org.
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